Education
About Us
Working with TipRanks
Follow Us
Ardent Health Partners, Inc. (ARDT)
NYSE:ARDT
Top Page
Ardent Health Partners, Inc.
(NYSE:ARDT)
Select Model
Select Model
Rating:68Neutral
Price Target:
$9.50
▲(5.91% Upside)
Ardent Health Partners, Inc. shows strong valuation and positive corporate events, but technical indicators suggest bearish momentum. Financial performance is solid, though profitability and leverage remain areas for improvement. Earnings call insights are positive but tempered by cost pressures.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective service offerings, supporting long-term business expansion.
Cash Flow Generation
Robust cash flow generation enhances financial flexibility, allowing for strategic investments and debt reduction, supporting sustainability.
Cost Optimization Program
The IMPACT program's cost savings initiatives are set to improve margins and operational efficiency, bolstering long-term profitability.
Negative Factors
Profitability Margins
Low net profit margins suggest challenges in cost management, potentially affecting long-term profitability and competitive positioning.
Industry Cost Pressures
Rising costs, especially in professional fees, could squeeze margins and impact financial performance, posing a risk to sustained growth.
Leverage Levels
High leverage levels may limit financial flexibility and increase risk, potentially affecting the company's ability to invest in growth.
Ardent Health Partners, Inc. (ARDT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.28B
Dividend YieldN/A
Average Volume (3M)407.60K
Price to Earnings (P/E)6.2
Beta (1Y)0.50
Revenue Growth10.86%
EPS Growth125.05%
CountryUS
Employees19,200
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.17
Shares Outstanding143,187,680
10 Day Avg. Volume333,763
30 Day Avg. Volume407,603
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.00
Price to Sales (P/S)0.38
P/FCF Ratio17.74
Enterprise Value/Market Cap3.15
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit0.91
Enterprise Value/Ebitda7.34
Forecast
1Y Price Target
$13.67Price Target Upside52.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ardent Health Partners, Inc. Business Overview & Revenue Model
Company DescriptionArdent Health Partners, LLC owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health Partners, LLC is a subsidiary of EGI-AM Investments, L.L.C.
How the Company Makes MoneyArdent Health Partners generates revenue primarily through patient services, which include hospital admissions, outpatient procedures, and specialty care services. The company bills patients and their insurance providers for services rendered, with revenue derived from both private insurance and government programs such as Medicare and Medicaid. Key revenue streams include inpatient services, outpatient services, diagnostic imaging, and surgical services. Additionally, Ardent may engage in partnerships with insurance companies and other healthcare organizations, allowing it to expand its service offerings and enhance its revenue opportunities. The company also focuses on operational efficiency and patient volume growth to increase its profitability.
Ardent Health Partners, Inc. Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 04, 2026
Earnings Call Sentiment Neutral
The earnings call reflected strong revenue and EBITDA growth and robust demand in key markets. However, persistent cost pressures, particularly from professional fees and payer denials, led to a revision in EBITDA guidance. The IMPACT program is a positive step towards cost optimization, but industry headwinds remain a challenge.Q3-2025 Updates
Positive Updates
Strong Revenue and EBITDA Growth
Third quarter revenue increased 8.8% to $1.58 billion. Adjusted EBITDA grew 46% in the third quarter to $143 million, with margins expanding 240 basis points to 9.1%.
Growth in Surgical Volumes
Surgical volumes improved with total surgeries up 1.4% in the third quarter, reversing a small decline of 0.4% in the first half of the year. Inpatient surgery growth was 9.7%.
Improved Cash Flow and Leverage
Cash flow from operating activities was strong at $154 million compared to $90 million for the third quarter of 2024. Lease-adjusted net leverage improved from 2.7x to 2.5x.
IMPACT Program for Cost Optimization
The IMPACT program is expected to generate an annual benefit of more than $40 million through contract renegotiations and targeted staffing adjustments.
Sustained Demand in Key Markets
Markets are growing 2x to 3x faster than the national average, driven by demographic tailwinds and rising care complexity.
Negative Updates
Revised EBITDA Guidance
Full-year adjusted EBITDA guidance revised to $530 million to $555 million due to persistent industry-wide cost pressures, notably professional fees and payer denials.
Professional Fees and Payer Denials Impact
Professional fees increased 11% in the third quarter, impacting adjusted EBITDA guidance. Payer denials also increased, further affecting financial performance.
Nonrecurring Items Affecting Financials
A $43 million revenue reduction due to a change in accounting estimate and a $54 million increase in liability reserves related to New Mexico market pressures.
Company Guidance
During the Ardent Health Third Quarter 2025 Earnings Conference Call, significant metrics and guidance were provided. Ardent's adjusted EBITDA year-to-date increased by 30%, with a third-quarter rise of 46% to $143 million, expanding margins by 240 basis points to 9.1%. Admissions grew by 5.8%, and adjusted admissions increased by 2.9%, while revenue climbed 8.8% or 11.7% excluding a one-time adjustment. Despite robust demand and surgical trends, persistent industry-wide cost pressures, notably in professional fees and payer denials, led to a revised full-year adjusted EBITDA guidance range of $530 million to $555 million. The company's IMPACT program aims to deliver efficiencies worth over $40 million annually, contributing to sustainable growth and margin expansion. Ardent maintains a strong balance sheet with total cash of $609 million and available liquidity of $904 million, positioning it for long-term shareholder value creation and strategic growth.Ardent Health Partners, Inc. Financial Statement Overview
Summary
Ardent Health Partners, Inc. shows strong revenue and cash flow growth, with a solid gross profit margin. However, the net profit margin and high debt-to-equity ratio indicate areas for improvement. Overall, the company exhibits potential for stability and growth.Income Statement
Ardent Health Partners, Inc. shows a solid revenue growth rate of 2.05% TTM, indicating a positive trajectory in revenue generation. The gross profit margin of 64.11% TTM is strong, reflecting efficient cost management. However, the net profit margin of 3.24% TTM is relatively low, suggesting room for improvement in profitability. EBIT and EBITDA margins are moderate at 6.39% and 8.89% TTM, respectively, indicating stable operational efficiency.75
Positive
Balance Sheet
The company's debt-to-equity ratio has improved to 1.84 TTM from previous years, showing a reduction in leverage, but it remains relatively high, indicating potential financial risk. The return on equity (ROE) of 17.09% TTM is healthy, suggesting effective utilization of shareholder equity. However, the equity ratio of 24.02% TTM indicates a lower proportion of equity financing, which could be a concern for financial stability.65
Positive
Cash Flow
Ardent Health Partners, Inc. demonstrates a strong free cash flow growth rate of 43.24% TTM, highlighting improved cash generation capabilities. The operating cash flow to net income ratio of 0.39 TTM and free cash flow to net income ratio of 0.43 TTM suggest a moderate conversion of income into cash, indicating decent cash flow management.70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.33B | 5.97B | 5.41B | 5.13B | 4.16B | 3.00B |
| Gross Profit | 4.47B | 4.93B | 5.27B | 4.17B | 4.16B | 3.00B |
| EBITDA | 551.64M | 574.93M | 350.00M | 531.70M | 281.84M | 230.91M |
| Net Income | 205.06M | 210.34M | 50.29M | 188.91M | -143.02M | -35.65M |
Balance Sheet | ||||||
| Total Assets | 5.15B | 4.96B | 5.10B | 4.86B | 2.75B | 2.37B |
| Cash, Cash Equivalents and Short-Term Investments | 609.44M | 556.78M | 437.58M | 456.12M | 59.66M | 71.96M |
| Total Debt | 2.28B | 2.28B | 2.40B | 2.39B | 1.26B | 952.69M |
| Total Liabilities | 3.52B | 3.43B | 4.02B | 3.81B | 2.03B | 1.61B |
| Stockholders Equity | 1.24B | 1.13B | 670.90M | 639.05M | 331.64M | 377.72M |
Cash Flow | ||||||
| Free Cash Flow | 154.89M | 127.52M | 84.29M | -189.47M | -1.07M | -2.06M |
| Operating Cash Flow | 364.07M | 315.03M | 221.70M | -38.36M | 159.59M | 119.47M |
| Investing Cash Flow | -233.44M | -220.46M | -137.98M | 46.58M | -525.11M | -983.27M |
| Financing Cash Flow | -84.33M | 24.64M | -102.26M | -270.33M | 353.22M | 843.15M |
Ardent Health Partners, Inc. Technical Analysis
Negative
8.97
Price Trends
11.26
Negative
12.14
Negative
12.64
Negative
Market Momentum
-0.53
Negative
37.05
Neutral
70.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARDT, the sentiment is Negative. The current price of 8.97 is above the 20-day moving average (MA) of 8.82, below the 50-day MA of 11.26, and below the 200-day MA of 12.64, indicating a neutral trend. The MACD of -0.53 indicates Negative momentum. The RSI at 37.05 is Neutral, neither overbought nor oversold. The STOCH value of 70.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARDT.
Ardent Health Partners, Inc. Risk Analysis
Ardent Health Partners, Inc. disclosed 54 risk factors in its most recent earnings report. Ardent Health Partners, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ardent Health Partners, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $2.15B | 21.38 | 9.94% | 1.80% | 23.74% | -18.99% | |
69 Neutral | $1.84B | 17.03 | 5.57% | 1.69% | -22.96% | -59.35% | |
68 Neutral | $1.28B | 6.21 | 18.28% | ― | 10.86% | 125.05% | |
61 Neutral | $1.32B | 12.13 | 3.49% | ― | 4.58% | -61.50% | |
61 Neutral | $2.59B | -8.29 | -214.33% | ― | 3.93% | -42.22% | |
58 Neutral | $1.82B | 24.19 | ― | ― | 15.48% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ARDT
Ardent Health Partners, Inc.
8.97
-7.94
-46.95%
ACHC
Acadia Healthcare
14.30
-23.66
-62.33%
BKD
Brookdale Senior Living
10.89
5.82
114.79%
NHC
National Healthcare
138.57
31.48
29.40%
SEM
Select Medical
14.84
-3.82
-20.47%
AVAH
Aveanna Healthcare Holdings
8.71
4.05
86.91%
Ardent Health Partners, Inc. Corporate Events
Stock BuybackBusiness Operations and Strategy
Ardent Health Announces $50M Stock Repurchase Program
Positive
Nov 18, 2025
On November 17, 2025, Ardent Health, Inc. announced a $50 million stock repurchase program authorized by its Board of Directors. This initiative allows the company to buy back its common stock through various methods without a specified expiration date, using existing cash and cash equivalents. The program, which adheres to federal securities laws, is flexible and can be modified or terminated at any time, reflecting the company’s strategic approach to managing its capital and potentially enhancing shareholder value.
Private Placements and FinancingBusiness Operations and Strategy
Ardent Health Partners Amends Credit Agreements for Flexibility
Positive
Sep 23, 2025
On September 18, 2025, Ardent Health, Inc., along with its subsidiary AHP Health Partners, Inc., and other related parties, entered into significant amendments to their existing credit agreements with Bank of America and other financial institutions. The amendments included refinancing outstanding term loans, extending the maturity date to September 18, 2032, reducing interest rates by 50 basis points, and updating certain financial covenants. These changes are expected to improve the company’s financial flexibility and reduce borrowing costs.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.